![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 28, 21532-21538, July 14, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
*
From the Center for Biomembranes and Lipid Enzymology, Department of Lipid Biochemistry, Institute of Biomembranes, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands
Received for publication, March 16, 2000, and in revised form, May 1, 2000
| |
ABSTRACT |
|---|
|
|
|---|
The charge isomers of bovine brain PI-TP Phosphatidylinositol transfer protein
(PI-TP)1 is a ubiquitous
protein that has been shown to play an essential role in secretion (vesicle flow) and in phospholipase C-dependent signaling
as was established in reconstituted systems (1-4). In addition, PI-TP may have a role in delivering substrate to the phosphatidylinositol 3-kinase complex (5, 6). Two isoforms of PI-TP have been identified,
PI-TP Localization studies by indirect immunofluorescence and by
microinjection of fluorescently labeled PI-TPs have shown that PI-TP Two charge isomers of PI-TP Materials--
Egg yolk PC, soybean PI, phosphatidic acid,
phosphatidylserine, PMA, ATP, phosphoserine, phosphothreonine, and
phosphotyrosine were obtained from Sigma. The pBluescript
SK Purification of Protein Kinase C--
PKC was purified from rat
brain by a modified procedure previously described by Huang et
al. (20). Rat brains (20-40 g of tissue) were homogenized, and
the cytosolic fraction was subsequently purified on DEAE-Sepharose,
Sephacryl 200 and phenyl-Sepharose columns. The purified enzyme has a
specific activity of 200 nmol of phosphate/min/mg protein when assayed
with histone IIIs as substrate. The purified enzyme is stable for
several months when kept at Purification of Bovine PI-TP Preparation of Recombinant PI-TP Site-directed Mutagenesis of Recombinant PI-TP Purification of wild type and Mutant His6-tagged
PI-TP Phospholipid Transfer Activity Assay--
PI and PC transfer
activities were determined in a continuous fluorescence assay using
2-pyrenyl-decanoyl-PI or -PC as substrates. (11, 17). Measurements were
performed using a fluorimeter (Photon Technology International)
equipped with a thermostated cuvette holder and a stirring device.
Phosphorylation of PI-TP in Vitro by Protein Kinase
C--
PI-TP Phosphorylation of PI-TP Phosphopeptide and Phosphoamino Acid Analysis--
After
identification by autoradiography, the 32P-labeled PI-TP
For phosphopeptide mapping the trichloroacetic acid pellet was
dissolved in performic acid, and oxidation was performed for 1-2 h on
ice. After lyophilization the sample was and incubated with
TPCK-trypsin in 50 mM ammonium bicarbonate (200 µg/ml) at 37 °C for 5 h. The incubation was repeated by the addition of fresh trypsin, and the sample was lyophilized. The phosphopeptides were
separated on cellulose TLC plates. In the first dimension electrophoresis was performed using the pH 1.9 buffer; in the second
dimension TLC was performed in n-butanol:pyridine:glacial acetic acid:H2O (75:50:15:60 v/v/v/v). Radioactive
phosphopeptides were identified by autoradiography.
Identification of the Phosphorylation Site--
PI-TP Preparation of Myc-tagged PI-TP Transfection of NIH3T3 Cells with the Myc-tagged
Constructs--
NIH3T3 cells were seeded 24 h prior to
transfection at 1 × 104 cells/cm2. Cells
were transfected with 2 µg of the pBK-CMV-Myc-PI-TP Immunolocalization--
The localization of endogenous PI-TP LysoPI Production in Vivo--
The effect of PMA and PDGF on the
production of lysoPI in NIH3T3 cells before and after stimulation with
PMA or PDGF was determined as described in Ref. 12. Briefly, NIH3T3
cells were cultured in a 6-well plate to 80% confluency. The cell
cultures were incubated for 48 h with 2 µCi of
[3H]-myo-inositol in HEPES-buffered DF medium
without inositol containing 2% dialyzed newborn calf serum. Cultures
were washed twice with phosphate-buffered saline and incubated for 10 min at 37 °C with DF medium (without inositol) containing 0.3%
bovine serum albumin and 10 mM LiCl. Subsequently, PMA (50 ng/ml) or PDGF (20 ng/ml) was added, and the incubation was continued
for another 15 min. The cells were washed twice with phosphate-buffered
saline and scraped in 1 ml of Kinetic Analysis of Phosphorylation--
The
PKC-dependent phosphorylation of the charge isomers
PI-TP Phosphopeptide Mapping and Phosphoamino Acid
Analysis--
Two-dimensional analysis of tryptic
32P-labeled peptides showed that PI-TP Determination of the Phosphorylation Site--
To determine the
PKC phosphorylation site of the in vitro phosphorylated
PI-TP Transfer Activity of the PI-TP
Under optimal conditions 10-15% of PI-TP
As shown in Ref. 12, wtPI-TP Relocalization and LysoPI Formation--
Stimulation of NIH3T3
cells with PMA for 15 min resulted in an extensive relocalization of
PI-TP Analysis of the amino acid sequence of mammalian PI-TP Replacement of Ser-166 with an Ala or Asp residue yielded a PI-TP Apart from being essential for proper folding and, hence, for in
vitro phospholipid transfer activity, Ser-166 is also the single
site of PKC phosphorylation. Very interestingly, the rate of
phosphorylation was dependent on the phospholipid ligand bound to
PI-TP In a previous study we have shown that activation of PKC in Swiss
mouse 3T3 cells induced a translocation of PI-TP
(i.e. PI-TP
I containing a phosphatidylinositol (PI)
molecule and PI-TP
II containing a phosphatidylcholine (PC) molecule)
were phosphorylated in vitro by rat brain protein kinase C
(PKC) at different rates. From the double-reciprocal plot, it was
estimated that the Vmax values for PI-TP
I
and II were 2.0 and 6.0 nmol/min, respectively; the Km values for both charge isomers were about equal,
i.e. 0.7 µM. Phosphorylation of charge
isomers of recombinant mouse PI-TP
confirmed that the PC-containing
isomer was the better substrate. Phosphoamino acid analysis of in
vitro and in vivo 32P-labeled PI-TP
s
showed that serine was the major site of phosphorylation. Degradation
of 32P-labeled PI-TP
by cyanogen bromide followed by
high pressure liquid chromatography and sequence analysis yielded one
32P-labeled peptide (amino acids 104-190). This peptide
contained Ser-148, Ser-152, and the consensus PKC phosphorylation site
Ser-166. Replacement of Ser-166 with an alanine residue confirmed that indeed this residue was the site of phosphorylation. This mutation completely abolished PI and PC transfer activity. This was also observed when Ser-166 was replaced with Asp, implying that this is a
key amino acid residue in regulating the function of PI-TP
. Stimulation of NIH3T3 fibroblasts by phorbol ester or platelet-derived growth factor induced the rapid relocalization of PI-TP
to
perinuclear Golgi structures concomitant with a 2-3-fold increase in
lysophosphatidylinositol levels. This relocalization was also observed
for Myc-tagged wtPI-TP
expressed in NIH3T3 cells. In contrast, the
distribution of Myc-tagged PI-TP
(S166A) and Myc-tagged
PI-TP
(S166D) were not affected by phorbol ester, suggesting that
phosphorylation of Ser-166 was a prerequisite for the relocalization to
the Golgi. A model is proposed in which the PKC-dependent
phosphorylation of PI-TP
is linked to the degradation of PI.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
and PI-TP
(7-9). Both isoforms transfer
phosphatidylinositol (PI) and phosphatidylcholine (PC) between
membranes in vitro (10). PI-TP
expresses an additional
activity for sphingomyelin (7, 11). In studies with the reconstituted
systems, PI-TP
and
behaved similarly. Recently, PI-TP
overexpressed in NIH3T3 cells was shown to enhance the constitutive
levels of lysophosphatidylinositol (lysoPI) (12). Overexpression of
PI-TP
in these cells had no effect on lysoPI formation but
stimulated the conversion of ceramide into sphingomyelin (13). In
addition to these soluble PI-TPs, a membrane-bound form of PI-TP was
detected containing a PI-TP
homology domain at the N terminus (amino
acids 1-257) and six putative membrane-spanning domains. This retinal
degeneration B (RdgB) protein was originally identified in
Drosophila (14).
is mainly localized in the nucleus and in the cytosol and that PI-TP
is mainly associated with the Golgi membranes (7, 8). Upon stimulation
of Swiss mouse 3T3 fibroblasts by growth factors that activate the PI
signaling pathway or by phorbol 12-myristate 13-acetate (PMA), PI-TP
became rapidly associated with the Golgi membranes. Under these
conditions PI-TP
was found to be phosphorylated, suggesting that
this modification may be a prerequisite for its association with the
Golgi. (15, 16). PI-TP
was also a substrate for protein kinase C
(PKC) in vitro in agreement with the presence of five
putative phosphorylation sites: Thr-59, Thr-169, Thr-198, Thr-251, and
Ser-166 (15, 16).
are present in tissues and cells of
which one isomer carries a PI molecule (PI-TP
I) and the other a PC
molecule (PI-TP
II) (17). The cellular concentration of PI-TP
I is
about 8-fold higher as compared with that of PI-TP
II. Because the
affinity of PI-TP
for PC is about 16-fold lower than the affinity
for PI, the relative amounts of the two isomers reflect the accessible
pools of PI and PC in the cell. To date, no comparable charge isomers
of PI-TP
have been detected. The physiological significance of the
two charge isomers of PI-TP
is not yet known. It has been suggested
that the yeast analogue of PI-TP, SEC14p, acts as a sensor of these
phospholipid pools in the Golgi inasmuch as that the two charge isomers
affect PI and PC metabolism differently (18). Given the ability of
PI-TP
to be involved in both PI and PC metabolism (12, 19), one may
expect a regulatory mechanism in the cell to be able to discriminate
between PI-TP
I and II. Because PI-TP
is a substrate for PKC, we
have investigated whether the phospholipid bound to PI-TP
has an
effect on the in vitro phosphorylation. It will be shown
that PI-TP
II is more rapidly phosphorylated by PKC than PI-TP
I.
Both charge isomers have one major phosphorylation site (Ser-166),
replacement of which with Ala or Asp completely abolished the transfer
activity. A model will be presented in which the phosphorylation of
PI-TP
is linked to the agonist-induced production of lysoPI.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
vector and the Quickchange site-directed mutagenesis
kit were purchased from Stratagene (La Jolla, CA). The oligonucleotides were synthesizsed by Eurogentec, Belgium. The pET-15b vector was obtained from Novagen (Madison, WI). The Escherichia coli
strain BL21(DE3) was obtained from Dr. J. H. Veerkamp (Department
of Biochemistry, University of Nijmegen, Nijmegen, The Netherlands). Isopropyl-
-D-thiogalactopyranoside was purchased from
Promega (Madison, WI). Ni2+-High Bond matrix was from
Invitrogen (San Diego, CA). [
-32P]ATP (3000 Ci/mmol)
was obtained from Amersham Pharmacia Biotech. Cellulose TLC plates and
TPCK-trypsin were purchased from Merck KGaA. The FuGENE6 Transfection
Reagent and the anti-c-Myc monoclonal antibody were from Roche
Molecular Biochemicals.
80 °C in 50% glycerol and 0.01%
Triton X-100.
I and II and of Recombinant Mouse
PI-TP
--
PI-TP
I and II were purified from bovine brain cytosol
as described by van Paridon et al. (17). The cDNA
encoding mouse PI-TP
was expressed in E. coli, and the
protein was purified as described by Geijtenbeek et al.
(16).
I and II--
The mouse
recombinant PI-TP
(recPI-TP
) purified from E. coli
contains one molecule of phosphatidylglycerol (PG) (16). To exchange
the PG molecule for a PI or PC molecule, recPI-TP
(28 nmol) was
incubated with PI (385 nmol) present in unilamellar vesicles consisting
of PI:PC (30:70 mol %) or with PC (900 nmol) present in vesicles
consisting of PC:phosphatidic acid (70:30 mol %). Vesicles were
prepared in 20 mM Tris buffer, pH 7.6, 50 mM
NaCl by sonication under nitrogen for 10 min. Vesicles and protein were
incubated for 15 min at 37 °C. The reaction was stopped by the
addition of MgCl2 to a final concentration of 5 mM. Protein and vesicles were separated on a DEAE-cellulose
column that was equilibrated in 20 mM Tris, pH 7.6, 50 mM NaCl, 5 mM MgCl2. The recPI-TP
eluted in the run-through and the negatively charged vesicles were retarded on the column (17). The protein content was
determined using the Bradford assay (21). The products of the exchange
reaction were analyzed by isoelectric focussing (16).
--
The
PI-TP
cDNA cloned into the pBluescript vector (pBlue-wtPI-TP
)
(16) was used for site-directed mutagenesis using the Quickchange
site-directed mutagenesis method according to the manufacturer's
instruction (Stratagene). Ser-166 was replaced by Ala using the
following mutagenic oligonucleotides: sense primer, 5'-CCAGCAAAATTTAAGGCTGTCAAAACAGGACGC-3';
antisense primer, 5'-GCGTCCTGTTTTGACAGCCTTAAATTTTGCTGG-3'. The
bold nucleotides encode the mutated amino acid (Ser-166 to Ala-166),
and the underlined nucleotide is a mutation that does not result in a
change in amino acid composition, but it deletes a DraI
restriction site. Incorporation of the mutagenic oligonucleotides into
the construct (pBlue-PI-TP
(S166A) was checked by restriction enzyme
analysis and by sequencing. Both the mutated and wtPI-TP
cDNAs
were cloned into the pET-15b expression vector. Expression of these
constructs yielded wtPI-TP
or PI-TP
(S166A) fused to an N-terminal
peptide containing six histidine residues. A mutant PI-TP
in which
Ser-166 was replaced with Asp-166 was obtained in a similar way using
the above oligonucleotides except that the bold nucleotides were
replaced for GAT (sense primer) and ATC (antisense primer).
--
The E. coli strain BL21(DE3) was transformed
by either the wtPI-TP
-pET15b or the mutant PI-TP
-pET-15b
construct. A 10-ml culture of each transformant grown overnight in LB
medium containing 50 µg/ml ampicillin was used to inoculate 1 liter
of LB medium (also containing 50 µg/ml ampicillin). Bacteria were
grown at 37 °C. At an A600 of 0.8, the
cultures were induced with 0.5 mM isopropyl-
-D-thiogalactopyranoside and grown for an
additional 3 h. His6-tagged wtPI-TP
or
His6-tagged mutant PI-TP
were purified from these
cultures. All further manipulations were performed at 4 °C. Bacteria
were harvested by centrifugation at 5,000 × g for 30 min. The pellet was resuspended in 50 ml of STE buffer (0.5 M NaCl, 10 mM Tris/HCl, 0.1 mM
EDTA, pH 7.5) and sonicated for 5 × 30 s at 80 W output with
a macrotip of a Branson Sonifier B12. The homogenate was centrifuged at
17,500 × g. The supernatant was collected and
extensively dialyzed against buffer A (18.3 mM
Na2HPO4, 1.3 mM
NaH2PO4, 500 mM NaCl, pH 7.8). The
dialyzed supernatant was applied to a Ni2+-High Bond column
(20 ml) and eluted with a linear gradient (200 ml) of 0-500
mM imidazol in buffer A (flow rate, 0.5 ml/min; fractions, 5 ml). The fractions were assayed for PI-TP
by measuring PI transfer activity and by Western blotting using an antibody against PI-TP. Purified His6-tagged wtPI-TP
and His6-tagged
mutant PI-TP
were used for the in vitro phosphorylation experiments.
(0.1-5 µg) was phosphorylated in a reaction volume
of 60 µl containing 20 mM Tris/HCl, pH 7.5, 7.5 mM magnesium acetate, 10 µg/ml leupeptin, 10 µM ATP, and 1-2 µCi of [
-32P]ATP. The
Ca2+/phospholipid-independent phosphorylation was
determined in the presence of 1 mM EGTA, and the
Ca2+/phospholipid-dependent phosphorylation was
determined in the presence of 1 mM Ca2+, 96 µg/ml phosphatidylserine, and 3.2 µg/ml diacylglycerol. The mixture
was incubated for 10 min at 37 °C, and the reaction was terminated
by the addition of 600 µl of cold acetone. Bovine serum albumin (1 µg) was added, and after 30 min on ice, the precipitated protein was
spun down, dissolved in sample buffer (125 mM Tris/HCl, pH
6.8, 5% (w/v) SDS, 12.5% (v/v) 2-mercaptoethanol, and 10% (v/v) glycerol) and analyzed by SDS-PAGE (15% gel) followed by autoradiography.
in Vivo--
Swiss mouse 3T3 cells
were cultured in Dulbecco's modified Eagle's medium containing 10%
newborn calf serum and buffered with NaHCO3 (44 mM) in a 7.5% CO2 atmosphere. Near-confluent
cell cultures in 75-cm2 flasks were labeled for 4.5 h
with 1.5 mCi of carrier-free [32P]Pi in 6 ml
of phosphate-free Ham's F-12 (DF) medium containing 5% newborn calf
serum. PMA (100 ng/ml) was present during the last 15 min of the
labeling. The membrane-free supernatant was prepared, and the
immunoprecipitation procedure was carried out as described by Snoek
et al. (15).
bands were excised from the dried gel and eluted as described by Boyle
et al. (22). Briefly, the gel slices were homogenized in 50 mM ammonium bicarbonate, pH 7.3-7.6, SDS (final
concentration, 0.1%), and 2-mercaptoethanol (final concentration, 1%)
were added, and the samples were boiled for 5 min. After incubation of
the mixture at 37 °C for 2 h, the gel was spun down and the
supernatant containing the 32P-labeled proteins was
collected. A second elution with 0.1% SDS and 1% 2-mercaptoethanol
was carried out on the gel pellet. Carrier protein (boiled RNase, 10 µg) and trichloroacetic acid (final concentration, 12%) was added to
the combined supernatant fractions, and the samples were incubated on
ice for 1 h. The trichloroacetic acid precipitate was washed with
cold ethanol and dried. For phosphoamino acid analysis, the pellet was
dissolved in 6 M HCl and hydrolyzed for 1 h at
110 °C. The HCl was removed by lyophilization, and the pellet was
dissolved in pH 1.9 buffer (glacial acetic acid:formic acid
(88%):H2O; 78:25:897 v/v/v). A mixture of phosphoserine, phosphothreonine, and phosphotyrosine (1 µg of each) was added. The
32P-labeled phosphoamino acids were separated by
two-dimensional electrophoresis on 20 × 20-cm cellulose TLC
plates. The first dimension was in buffer pH 1.9, and the second
dimension was in glacial acetic acid:pyridine:H2O (50:5:945
v/v/v), pH 3.5. After electrophoresis the plates were dried, the
phosphoamino acids were visualized by staining with 0.2% (w/v)
ninhydrin in acetone, and the 32P-labeled amino acids were
identified by autoradiography.
was
phosphorylated as described above with the following changes. The ATP
concentration was 1 mM with a trace of
[
-32P]ATP, and the incubation time was 2-4 h at
30 °C. The proteins were separated by SDS-PAGE, eluted, and
precipitated with 10% trichloroacetic acid as described above. The
pellet was digested with cyanogen bromide (2.5 mg/ml in 70% formic
acid, 50 nmol cyanogen bromide/nmol protein) by incubation for 24 h in the dark at room temperature. After lyophilization, the sample was
dissolved in 6 M guanidine HCl in 0.085% trifluoroacetic
acid, and the peptides were separated on a reverse phase column
C2/C18 (Amersham Pharmacia Biotech, SMART
system) with a 0-60% (v/v) acetonitril. The radioactive peak was
collected, and the N-terminal amino acid sequence of the
32P-labeled peptide was determined by automatic Edman
degradation using the 476A protein sequencer (Applied Biosystems).
--
The pBlue-wtPI-TP
,
pBlue-PI-TP
(S166A) and pBlue-PI-TP
(S166D) constructs were used to
generate Myc-tagged PI-TP
fusion proteins. The pBlue-PI-TP
constructs contained a SacI site upstream of the
translational start codon, an NcoI restriction site around the translational start codon, and a BamHI restriction site
downstream of the translational stop codon. The SacI and
NcoI sites were used to insert the linker encoding the
Myc-tagged into the coding sequence. The linker consisted of two
oligonucleotide primers carrying a SacI and an
NcoI sticky end. The oligonucleotides used were:
5'-CATGGAACAAAAACTTATTTCTGAAGAAGATCTGC-3' and
5'-CATGGCAGATCTTCTTCAGAAATAAGTTTTTGTTCCATGAGCT-3'. The underlined nucleotides of primer 2 represent the
NcoI sticky end, and the bold nucleotides represent the
SacI sticky end; the remaining bases are complementary to
primer 1. The primers (10 µM each) were annealed at
60 °C for 15 min. After cooling to room temperature, the resulting
linker was ligated into the pBlue-PI-TP
constructs that were
previously digested with SacI and NcoI. The ensuing constructs were digested with SacI and
BamHI, and the resulting DNA encoding Myc-tagged PI-TP
were ligated into the corresponding sites of the pBK-CMV expression
vector. The obtained constructs were denoted as pBK-CMV-Myc-wtPI-TP
,
pBK-CMV-Myc-PI-TP
(S166A), and pBK-CMV-Myc-PI-TP
(S166D).
Expression of these constructs yields PI-TP
fused to an N-terminal
peptide containing the 9E10 epitope (the peptide EQKLISEEDL) of the
human c-Myc protein (Myc-tagged).
constructs using the FuGENE6 Transfection Reagent kit according to the
manufacturer's instruction (Roche Molecular Biochemicals). The
following day the cells were reseeded at approximately 5 × 103 cells/cm2. After another 24 h, G418
(0.4 mg/ml) was added for selection of G418-resistant cells. Fresh
medium containing G418 was added every 4 days, and resistant clones
were identified after 3 weeks of growth.
,
Myc-tagged wtPI-TP
, Myc-tagged PI-TP
(S166A), and Myc-tagged
PI-TP
(S166D) in serum-starved (semi-quiescent) NIH3T3 cells was
determined before and after stimulation with PMA or platelet derived
growth factor (PDGF) as described in Ref. 15. Briefly, NIH3T3 cells
were made semi-quiescent by replacing the growth medium with
Dulbecco's modified Eagle's medium containing 0.5% newborn calf
serum. After 2 days the cells were incubated for 15 min at 37 °C
with PMA (50 ng/ml) or PDGF (20 ng/ml) and fixed with methanol
(endogenous PI-TP
) or paraformaldehyde (Myc-tagged PI-TP
s).
Endogenous PI-TP
was visualized by indirect immunofluorescence using
a polyclonal antibody directed against PI-TP
and
goat-anti-rabbit-Cy3 as the second antibody. Myc-tagged PI-TP
s were
visualized using a mouse monoclonal antibody directed against the
Myc-tagged and goat anti-mouse tetramethyl rhodamine isothiocyanate as
the second antibody.
20 °C methanol. The
[3H]inositol phospholipids were extracted and analyzed as
described previously (23).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
I and II from bovine brain was determined in vitro
as a function of concentration. From the Lineweaver-Burk plot it was
calculated that the Vmax of the phosphorylation
of PI-TP
I was 2.0 nmol/min and that of PI-TP
II 6.0 nmol/min (Fig.
1A). The Km
of either reaction was comparable (0.65 and 0.72 µM,
respectively). This implies that the affinity of rat brain PKC for both
isomers is the same, yet that PI-TP
containing a PC molecule is
phosphorylated at a faster rate than the protein containing a PI
molecule. To confirm these results we have done similar experiments on
mouse recPI-TP
. RecPI-TP
contains a PG molecule that can be
readily exchanged for either PI or PC (16). Phosphorylation of the
charge isomers of recPI-TP
by PKC confirmed that the PC-containing
protein was phosphorylated at a faster rate than the PI-containing
protein (Fig. 1B). In addition, phosphorylation of the
PG-containing recPI-TP
was comparable with that of the PC-containing
protein (data not shown). In comparison with the bovine PI-TP
s the
mouse recPI-TP
s were better substrates, with
Vmax values about 1 order of magnitude higher
and Km values 1 order of magnitude lower (0.1 µM).

View larger version (12K):
[in a new window]
Fig. 1.
Kinetic analysis of the in vitro
phosphorylation of PI-TP
by PKC.
The phosphorylation reaction was carried out as described under
"Experimental Procedures." The rate of phosphorylation as a
function of PI-TP
concentration is expressed as a Lineweaver-Burk
plot. A, bovine PI-TP
I (
) and PI-TP
II (
).
B, mouse recPI-TP
containing PI (
) or PC (
). The
values are representative of three independent experiments performed in
duplicate.
I, PI-TP
II and
recPI-TP
have one major phosphopeptide in common as well as a minor
one. The phosphopeptide map of PI-TP
II showed three additional minor
spots (Fig. 2). Phosphoamino acid analysis of the in vitro phosphorylated proteins
demonstrated that all three PI-TP
s are mainly phosphorylated on
serine (Fig. 3). The immunoprecipitated
PI-TP
from PMA-stimulated 32P-labeled Swiss mouse 3T3
cells was purified by SDS-PAGE. Phosphopeptide mapping and phosphoamino
acid analysis of 32P-labeled PI-TP
showed that in
vivo PI-TP
was exclusively phosphorylated on serine (data not
shown). In line with this result, the phosphopeptide map is very
similar to that of recPI-TP
(Fig. 2).

View larger version (80K):
[in a new window]
Fig. 2.
Phosphopeptide maps of bovine
PI-TP
I and II, mouse
recPI-TP
phosphorylated in vitro,
and mouse PI-TP
phosphorylated in
vivo. 32P-Labeled PI-TP
was degraded by trypsin,
and the phosphopeptides were separated on a thin layer plate followed
by autoradiography as described under "Experimental Procedures."
The arrow indicates the origin.

View larger version (11K):
[in a new window]
Fig. 3.
Phosphoamino acid analysis of
PI-TP
I, PI-TP
II, and
recPI-TP
. 32P-Labeled
PI-TP
was hydrolyzed by 6 M HCl and subjected to
two-dimensional separation on a thin layer plate. The positions of the
origin (as indicated by the arrow), phosphoserine
(S), phosphothreonine (T), phosphotyrosine
(Y), and inorganic phosphate (Pi) are
indicated.
, this protein was cleaved by cyanogen bromide, and the
peptides were separated on a reversed phase column. The 32P
label was detected in one peak that, as shown by automated Edman degradation, represented the cyanogen bromide peptide Lys-105 to
Met-191, containing three serine residues (i.e. Ser-148,
Ser-152, and Ser-166; data not shown). Given that the phosphoamino acid analysis showed serine as the preferred amino acid residue of phosphorylation and that in the labeled cyanogen bromide peptide only
Ser-166 is the predicted PKC phosphorylation site, this serine was
replaced with alanine by site-directed mutagenesis. Purified His6-tagged wtPI-TP
and His6-tagged
PI-TP
(S166A) were used as substrates for PKC. As shown in Fig.
4, PI-TP
(S166A) was not phosphorylated
by PKC (lanes 1-4), whereas wtPI-TP
was phosphorylated (lanes 5-8). To exclude the possibility that incorrect
folding was the cause of PI-TP
(S166A) not being phosphorylated by
PKC, we denatured the mutant and wtPI-TP
by boiling in SDS and
-mercaptoethanol, followed by SDS-PAGE electrophoresis and elution
of the protein. PKC-dependent phosphorylation of these
denatured proteins gave the same results as obtained with the native
proteins (data not shown). These results show unambiguously that
Ser-166 in PI-TP
is phosphorylated by PKC.

View larger version (29K):
[in a new window]
Fig. 4.
Phosphorylation of wtPI-TP
and PI-TP
(S166A). PI-TP
was
phosphorylated as described under "Experimental Procedures" and
subjected to SDS-PAGE analysis (A) and autoradiography
(B). Lanes 1 and 2, 1 µg of
PI-TP
(S166A); lanes 3 and 4, 2 µg of
PI-TP
(S166A); lanes 5 and 6, 1 µg of
wtPI-TP; lanes 7 and 8, 2 µg of wtPI-TP
;
lanes 9 and 10, PKC control. The samples in the
odd-numbered lanes were incubated in the absence of
Ca2+, phosphatidylserine, and diacylglycerol, and those in
the even-numbered lanes were incubated in the presence of
Ca2+, phosphatidylserine, and diacylglycerol.
Mutants--
Purified
His6-tagged wtPI-TP
was able to transfer PI, whereas
His6-tagged PI-TP
(S166A) lacked this activity (Fig.
5). Similarly, His6-tagged
PI-TP
(S166A) lacked PC transfer activity. As a control, Ser-152 was
replaced with Ala. The resulting His6-tagged
PI-TP
(S152A) had normal PI and PC transfer activity. This indicates
that Ser-166 is important for transfer activity. To investigate the
possibility that the lack of transfer activity was due to incorrect
folding during expression in E. coli, we have carried out
refolding experiments on inclusion bodies according to standard
procedures.2 In agreement
with the above observations, His6-tagged PI-TP
(S166A) could not be activated, whereas refolded His6-tagged
wtPI-TP
and His6-tagged PI-TP
(S152A) were fully
active.

View larger version (17K):
[in a new window]
Fig. 5.
In vitro phospholipid transfer
activity of mutant and wtPI-TP
. The
phospholipid transfer activity of the PI-TP
s was assayed as
described under "Experimental Procedures" by measuring the transfer
of fluorescently labeled PI (Pyr-PI) from quenched donor
vesicles to acceptor vesicles. To the donor vesicles in the cuvette
were subsequently added the acceptor vesicles (arrow I),
bovine serum albumin (arrow II), and different PI-TP
s
(arrow III). Line 1, wtPI-TP
; line
2, PI-TP
(S152A); line 3, PI-TP
(S166A); Line
4, PI-TP
(S166D).
was found to be
phosphorylated by PKC in vitro (15). In agreement with this
relatively low level of phosphorylation, the phospholipid transfer
activity was not affected by PKC treatment (data not shown). To further examine the effect of phosphorylation on transfer activity, a mutant of
PI-TP
was made in which Ser-166 was replaced with Asp to mimic
phosphorylated serine. As shown in Fig. 5, PI-TP
(S166D) was not
active in the phospholipid transfer activity assay, suggesting that the
phosphorylation of Ser-166 may constitute a regulatory step.
stimulates lysoPI formation in an
in vitro assay. Under comparable conditions PI-TP
(S166A) had no effect (data not shown). From this we conclude that PI-transfer activity is a prerequisite for PI-TP
to stimulate lysoPI formation.
to perinuclear membrane structures (Fig.
6). The same relocalization was observed
after stimulation with PDGF (data not shown). This is in agreement with a previous study on the relocalization of PI-TP
in Swiss mouse 3T3
cells (15). In the latter study it was shown that these perinuclear
structures were Golgi-like. To determine whether phosphorylation of
PI-TP
was required for the relocalization to the Golgi complex, NIH3T3 cells were transfected with the pBK-CMV-Myc-wtPI-TP
,
-PI-TP
(S166A), and -PI-TP
(S166D) constructs. The
localization of the Myc-tagged PI-TP
s was determined in
serum-starved cells using an antibody against the Myc-tagged. Similar
to the endogenous PI-TP
, Myc-tagged wtPI-TP
was localized
throughout the cytosol and in the nucleus and relocated to perinulcear
Golgi structures upon stimulation by PMA (data not shown). Myc-tagged
PI-TP
(S166A) and Myc-tagged PI-TP
(S166D) were also localized in
the cytosol and the nucleus. However, these mutants did not relocalize
upon stimulation by PMA, suggesting that phosphorylation of Ser-166 is
required for the relocalization to the Golgi. Given that the expression
of PI-TP
is involved in the regulation of phospholipase
A-dependent formation of lysoPI (12), we have determined
the cellular amount of lysoPI under the above conditions of PI-TP
translocation. Stimulation by PMA and PDGF increased the amount of
lysoPI 2- and 3-fold, respectively (Fig.
7). No significant effects were observed
on the levels of PI 4-phosphate and PI 4,5-bisphosphate.

View larger version (38K):
[in a new window]
Fig. 6.
Immunolocalization of
PI-TP
in stimulated and nonstimulated NIH3T3
fibroblast cells. Serum-starved (semi-quiescent) cells were
stimulated with PMA, fixed, and incubated with anti-PI-TP
antibody
(B). The control without PMA stimulation is shown in
A.

View larger version (24K):
[in a new window]
Fig. 7.
LysoPI production in NIH3T3 cells upon
stimulation with PMA or PDGF. [3H]Inositol-labeled
cells were stimulated for 15 min, and the distribution of
3H label in the inositol phospholipids was analyzed.
,
control;
, stimulated with PDGF (20 ng/ml);
, stimulated with PMA
(50 ng/ml). PIP, phosphatidylinositol 4-phosphate;
PIP2, phosphatidylinositol 4,5-bisphosphate.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
showed
the presence of five possible sequence motifs that are consensus phosphorylation sites for PKC (i.e. Thr-59, Thr-169,
Thr-198, Thr-251, and Ser-166) (15). A review on specific
phosphorylation sites for various PKC isoforms indicated that Ser-166
is the only putative site (24). In this study we have proven by peptide analysis and site-directed mutagenesis that indeed the phosphorylation of PI-TP
by rat brain PKC in vitro was restricted to
Ser-166. Stimulation of PKC in Swiss mouse 3T3 cells by phorbol ester
(PMA) also phosphorylated a serine residue of PI-TP
. Given that the tryptic peptide maps of the in vitro and in vivo
phosphorylated PI-TP
s were comparable, we presume that Ser-166 is
the site of PKC-dependent phosphorylation in intact cells.
species, which in vitro completely lacked PI and PC transfer activity. For comparison, replacement of Ser-152 with an Ala residue had no effect on the transfer activity. This indicates that the activity of PI-TP
is dependent on the presence of Ser-166. This residue may be essential for a correct folding of the active protein during its expression in E. coli. It is possible that
concomitant with the expression, Ser-166 may form a hydrogen bond with
the polar head group of the PG molecule that is normally present in recombinant wtPI-TP
(16). In the case of Ala-166 or Asp-166, this
hydrogen bond cannot be formed, resulting in a PI-TP
that cannot
interact with PG. This interaction may be important for PI-TP
to
fold properly during its synthesis in E. coli. Reactivation of native PI-TP
expressed in E. coli from inclusion
bodies was only possible when phospholipid was present in the refolding
buffer. Under these conditions of
refolding, inclusion bodies of PI-TP
(S166A) did not yield an active
protein. In addition, comparison of holo- and apo- species (with or
without a phospholipid ligand, respectively) of native PI-TP
indicated that binding of a phospholipid ligand is required for
obtaining the proper, more compact structure of holo-PI-TP
.
Apo-PI-TP
demonstrated a significant relaxation of the tertiary
structure (25). In a previous study it was reported that mutation of
the putative PKC phosphorylation site Thr-59 abolished the PI but not
the PC transfer activity (26). Based on this observation a model was
proposed where the phosphorylation/dephosphorylation of Thr-59 was
presented as a key event in the regulation of phospholipid transfer
activity in situ. However, because we have not found any
evidence for the phosphorylation of a threonine residue, it remains to
be established whether Thr-59 plays any role in this process
. Both for bovine and mouse PI-TP
, it was observed that the
Vmax was 2-3-fold higher with PC than with PI
as ligand. Because the Km values were comparable, we
concluded that the affinity of PKC for PI-TP
was not affected by the
ligand, yet that the charge difference between PI and PC resulted in a
different rate of phosphorylation. It is as yet impossible to determine the phosphorylation of PI-TP
I and II in situ as
conventional methods fail to distinguish between these charge isomers.
From the three-dimensional structure of the yeast PI-TP analogue
(SEC14p), we know that the polar head group of the bound phospholipid
molecule is exposed at the surface of the protein (27). If we assume that this is also the case in the mammalian PI-TP
, the polar head
group of the bound phospholipid could have an effect on the surface
characteristics of the protein and hence on the rate of phosphorylation. In crystallization studies of PI-TP
, we have observed that the conditions at which crystals were obtained were dependent on the bound phospholipid, suggesting a direct effect on the
surface charge and conformation.2 In the present study the
recombinant mouse PI-TP
was a better substrate for the rat brain PKC
as compared with the bovine PI-TP
. Apparently the minor differences
in isoelectric point and primary structure (16) have an effect on the
in vitro phosphorylation by rat brain PKC.
from the cytosol to
the Golgi complex (15). A similar translocation to the Golgi was
observed when NIH3T3 cells were activated by PMA or PDGF (Fig. 6). We
presume that phosphorylation of PI-TP
is required to make PI-TP
interact with the Golgi. This raises the question of what function
PI-TP
may fulfill at the Golgi. In previous studies PI-TP
was
shown to play an essential role in the ATP-dependent
formation of transport vesicles from the trans-Golgi network
in reconstituted systems (2, 28-30). It has been proposed that the
formation of these vesicles involves the local conversion of PI into
metabolites that cause the remodelling of the phospholipid bilayer in
the vicinity of a coated bud (28). PI-TP
would play a role in this
conversion by delivering PI as a substrate to PI kinases (31). However,
whether PI-TP
fulfills a role in the phosphorylation of PI in intact
cells has not been confirmed. Studies with NIH3T3 cells overexpressing
PI-TP
have indicated that the intracellular levels of lysoPI and
further metabolites glycerophosphoinositol, Ins(1)P and Ins(2)P were
constitutively increased (i.e. 3-6 fold) most likely as a
result of PI-TP
acting as a regulator of a PI-specific phospholipase
A2 (12). No evidence was obtained that in these
overexpressors PI-TP
had any effect on the phosphorylation of PI by
activation of PI kinases. Glycerophosphoinositol and its further
metabolites have been shown to act as a mitogen in certain cell lines
(32) and may possibly contribute to the enhanced growth rate of these
PI-TP
overexpressors (12). In cells overexpressing PI-TP
effects
on PI metabolism were not observed. Concomitant with the translocation
of PI-TP
to the Golgi, activation of wtNIH3T3 cells by PDGF and PMA
resulted in a 2-3-fold increase of lysoPI (Fig. 7). In view of our
evidence that levels of lysoPI are controlled by the amount of PI-TP
expressed, we presume that the PKC-dependent translocation
of PI-TP
to the Golgi results in more PI becoming available for
degradation by the phospholipase. Based on this hypothesis, we propose
a model explaining how the phosphorylation of PI-TP
results in an
enhanced lysoPI formation. As shown in the model presented in Fig.
8, the receptor-controlled activation of
PKC leads to a more rapid phosphorylation of the PC-containing PI-TP
than of the PI-containing PI-TP
. The phosphorylated form of
PI-TP
II is then translocated to the Golgi where in view of the high
preference for PI, the protein unloads its PC molecule and binds a PI
molecule. It can be expected that upon interaction with the Golgi, the
phospholipid exchange reaction and dephosphorylation of PI-TP
by a
protein phosphatase occurs. A similar protein phosphatase was proposed
in the model by Alb et al. (26). After its release from the
Golgi, PI-TP
delivers its bound PI to the PI-specific phospholipase
A2 to be degraded. The effect of the
phosphorylation/dephosphorylation of PI-TP
is that upon receptor
activation at the plasma membrane there is a rapid and controlled
increase of PI available for metabolism. The important implication of
this model is that the relative amount of PI- and PC-containing
PI-TP
s as controlled by the accessible PI and PC pools in the cell
can be shifted toward the PI-containing PI-TP
as a result of PKC
activation.

View larger version (27K):
[in a new window]
Fig. 8.
Model of the rapid PKC-dependent
phosphorylation of the PC-containing PI-TP
(PI-TP
I) as a mechanism to increase the
amount of PI available for breakdown by phospholipase
A2. This model presents an explanation for the
relationship between the PKC-dependent phosphorylation of
PI-TP
II, its translocation to the Golgi, and the increased levels of
lysoPI. The proposed protein phosphatase (PPase) in the
Golgi ensures the detachment of the PI-containing PI-TP
. The PI
bound to PI-TP
is delivered as a substrate for phospholipase
A2 (PLA2).
| |
ACKNOWLEDGEMENT |
|---|
We are grateful to F. van der Lecq for carrying out the sequence analysis.
| |
FOOTNOTES |
|---|
* This work was supported by the Netherlands Organization for Scientific Research.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed. Tel.: 31-30-2534668;
Fax: 31-30-2522478; E-mail: g.t.snoek@chem.uu.nl.
Published, JBC Papers in Press, May 5, 2000, DOI 10.1074/jbc.M002203200
2 B. Bouma, J. Westerman, C. M. van Tiel, and K. W. A. Wirtz, to be published.
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
PI-TP, phosphatidylinositol transfer protein;
recPI-TP
, mouse recombinant
PI-TP
;
PI, phosphatidylinositol;
PC, phosphatidylcholine;
PG, phosphatidylglycerol;
lysoPI, lysophosphatidylinositol;
PMA, phorbol
12-myristate 13-acetate;
PKC, protein kinase C;
PDGF, platelet-derived
growth factor;
PAGE, polyacrylamide gel electrophoresis;
TPCK-trypsin, tosylphenylalanyl chloromethyl ketone-treated trypsin;
wt, wild
type.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Fensome, A., Cunningham, E., Prosser, S., Tan, S. K., Swigart, P., Thomas, G., Hsuan, J., and Cockcroft, S. (1996) Curr. Biol. 6, 730-738 |
| 2. | Ohashi, M., de Vries, K. J., Frank, R., Snoek, G. T., Bankaitis, V., Wirtz, K. W. A., and Huttner, W. B. (1995) Nature 377, 544-547 |
| 3. | Thomas, G. M., Cunningham, E., Fensome, A., Ball, A., Totty, N. F., Truong, O., Hsuan, J. J., and Cockcroft, S. (1993) Cell 74, 919-928 |
| 4. | Cockcroft, S., Ball, A., Fensome, A., Hara, S., Jones, D., Prosser, S., and Swigart, P. (1997) Biochem. Soc. Trans. 25, 1125-1131 |
| 5. | Panaretou, C., Domin, J., Cockcroft, S., and Waterfield, M. D. (1997) J. Biol. Chem. 272, 2477-2485 |
| 6. | Kular, G., Loubtchenkov, M., Swigart, P., Whatmore, J., Ball, A., Cockcroft, S., and Wetzker, R. (1997) Biochem. J. 325, 299-301 |
| 7. | de Vries, K. J., Heinrichs, A. A., Cunningham, E., Brunink, F., Westerman, J., Somerharju, P. J., Cockcroft, S., Wirtz, K. W. A., and Snoek, G. T. (1995) Biochem. J. 310, 643-649 |
| 8. | de Vries, K. J., Westerman, J., Bastiaens, P. I., Jovin, T. M., Wirtz, K. W. A., and Snoek, G. T. (1996) Exp. Cell. Res. 227, 33-39 |
| 9. | Tanaka, S., and Hosaka, K. (1994) J. Biochem. (Tokyo) 115, 981-984 |
| 10. | Wirtz, K. W. A. (1997) Biochem. J. 324, 353-360 |
| 11. | Westerman, J., de Vries, K. J., Somerharju, P., Timmermans-Hereijgers, J. L., Snoek, G. T., and Wirtz, K. W. A. (1995) J. Biol. Chem. 270, 14263-14266 |
| 12. | Snoek, G. T., Berrie, C. P., Geijtenbeek, T. B., van der Helm, H. A., Cadee, J. A., Iurisci, C., Corda, D., and Wirtz, K. W. A. (1999) J. Biol. Chem. 274, 35393-35399 |
| 13. | Van Tiel, C. M., Luberto, C., Snoek, G. T., Hannun, Y. A., and Wirtz, K. W. A. (2000) Biochem. J. 346, 537-543 |
| 14. | Vihtelic, T. S., Goebl, M., Milligan, S., O'Tousa, J. E., and Hyde, D. R. (1993) J. Cell Biol. 122, 1013-1022 |
| 15. | Snoek, G. T., Westerman, J., Wouters, F. S., and Wirtz, K. W. A. (1993) Biochem. J. 291, 649-656 |
| 16. | Geijtenbeek, T. B., de Groot, E., van Baal, J., Brunink, F., Westerman, J., Snoek, G. T., and Wirtz, K. W. A. (1994) Biochim. Biophys. Acta 1213, 309-318 |
| 17. | van Paridon, P. A., Visser, A. J., and Wirtz, K. W. A. (1987) Biochim. Biophys. Acta 898, 172-180 |
| 18. | Skinner, H. B., McGee, T. P., McMaster, C. R., Fry, M. R., Bell, R. M., and Bankaitis, V. A. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 112-116 |
| 19. | Monaco, M. E., Alexander, R. J., Snoek, G. T., Moldover, N. H., Wirtz, K. W. A., and Walden, P. D. (1998) Biochem. J. 335, 175-179 |
| 20. | Huang, K. P., Chan, K. F., Singh, T. J., Nakabayashi, H., and Huang, F. L. (1986) J. Biol. Chem. 261, 12134-12140 |
| 21. | Bradford, M. M. (1976) Anal. Biochem. 72, 248-254 |
| 22. | Boyle, W. J., van der Geer, P., and Hunter, T. (1991) Methods Enzymol. 201, 110-149 |
| 23. | Falasca, M., and Corda, D. (1994) Eur. J. Biochem. 221, 383-389 |
| 24. | Nishikawa, K., Toker, A., Johannes, F. J., Zhou, S., and Cantley, L. C. (1997) J. Biol. Chem. 272, 952-960 |
| 25. | Voziyan, P. A., Tremblay, J. M., Yarbrough, L. R., and Helmkamp, G. M., Jr. (1997) Biochemistry 36, 10082-10088 |
| 26. | Alb, J. G. J., Gedvilaite, A., Cartee, R. T., Skinner, H. B., and Bankaitis, V. A. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 8826-8830 |
| 27. | Sha, B., Phillips, S. E., Bankaitis, V. A., and Luo, M. (1998) Nature 391, 506-510 |
| 28. | Simon, J. P., Morimoto, T., Bankaitis, V. A., Gottlieb, T. A., Ivanov, I. E., Adesnik, M., and Sabatini, D. D. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 11181-11186 |
| 29. | Paul, K. S., Bogan, A. A., and Waters, M. G. (1998) FEBS Lett. 431, 91-96 |
| 30. | Jones, S. M., Alb, J. G., Jr., Phillips, S. E., Bankaitis, V. A., and Howell, K. E. (1998) J. Biol. Chem. 273, 10349-10354 |
| 31. | Cockcroft, S. (1997) FEBS Lett. 410, 44-48 |
| 32. | Falasca, M., Marino, M., Carvelli, A., Iurisci, C., Leoni, S., and Corda, D. (1996) Eur. J. Biochem. 241, 386-392 |
This article has been cited by other articles:
![]() |
Y.-H. Yeh, J. R. Ehrlich, X. Qi, T. E. Hebert, D. Chartier, and S. Nattel Adrenergic control of a constitutively active acetylcholine-regulated potassium current in canine atrial cardiomyocytes Cardiovasc Res, June 1, 2007; 74(3): 406 - 415. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Phillips, K. E. Ile, M. Boukhelifa, R. P.H. Huijbregts, and V. A. Bankaitis Specific and Nonspecific Membrane-binding Determinants Cooperate in Targeting Phosphatidylinositol Transfer Protein beta-Isoform to the Mammalian Trans-Golgi Network Mol. Biol. Cell, June 1, 2006; 17(6): 2498 - 2512. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. P. Morgan, A. Skippen, B. Segui, A. Ball, V. Allen-Baume, B. Larijani, J. Murray-Rust, N. McDonald, G. Sapkota, N. Morrice, et al. Phosphorylation of a Distinct Structural Form of Phosphatidylinositol Transfer Protein {alpha} at Ser166 by Protein Kinase C Disrupts Receptor-mediated Phospholipase C Signaling by Inhibiting Delivery of Phosphatidylinositol to Membranes J. Biol. Chem., November 5, 2004; 279(45): 47159 - 47171. [Abstract] [Full Text] [PDF] |
||||
|
|